These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 28924241)
1. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Nadeu F; Clot G; Delgado J; Martín-García D; Baumann T; Salaverria I; Beà S; Pinyol M; Jares P; Navarro A; Suárez-Cisneros H; Aymerich M; Rozman M; Villamor N; Colomer D; González M; Alcoceba M; Terol MJ; Navarro B; Colado E; Payer ÁR; Puente XS; López-Otín C; López-Guillermo A; Enjuanes A; Campo E Leukemia; 2018 Mar; 32(3):645-653. PubMed ID: 28924241 [TBL] [Abstract][Full Text] [Related]
2. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699 [TBL] [Abstract][Full Text] [Related]
3. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia. Amin NA; Seymour E; Saiya-Cork K; Parkin B; Shedden K; Malek SN Clin Cancer Res; 2016 Sep; 22(17):4525-35. PubMed ID: 27060156 [TBL] [Abstract][Full Text] [Related]
5. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136 [TBL] [Abstract][Full Text] [Related]
6. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254 [TBL] [Abstract][Full Text] [Related]
7. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377 [TBL] [Abstract][Full Text] [Related]
8. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis. Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470 [TBL] [Abstract][Full Text] [Related]
9. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression. Sutton LA; Rosenquist R Expert Rev Hematol; 2015 Feb; 8(1):71-8. PubMed ID: 25345442 [TBL] [Abstract][Full Text] [Related]
10. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198 [TBL] [Abstract][Full Text] [Related]
11. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Barrio S; Shanafelt TD; Ojha J; Chaffee KG; Secreto C; Kortüm KM; Pathangey S; Van-Dyke DL; Slager SL; Fonseca R; Kay NE; Braggio E Leukemia; 2017 Jan; 31(1):170-176. PubMed ID: 27469216 [TBL] [Abstract][Full Text] [Related]
12. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403 [TBL] [Abstract][Full Text] [Related]
13. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978 [TBL] [Abstract][Full Text] [Related]
14. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598 [TBL] [Abstract][Full Text] [Related]
15. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Malcikova J; Stano-Kozubik K; Tichy B; Kantorova B; Pavlova S; Tom N; Radova L; Smardova J; Pardy F; Doubek M; Brychtova Y; Mraz M; Plevova K; Diviskova E; Oltova A; Mayer J; Pospisilova S; Trbusek M Leukemia; 2015 Apr; 29(4):877-85. PubMed ID: 25287991 [TBL] [Abstract][Full Text] [Related]
16. The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study. De Luca G; Cerruti G; Lastraioli S; Conte R; Ibatici A; Di Felice N; Morabito F; Monti P; Fronza G; Matis S; Colombo M; Fabris S; Ciarrocchi A; Neri A; Menichini P; Ferrarini M; Nozza P; Fais F; Cutrona G; Dono M Hematol Oncol; 2022 Dec; 40(5):962-975. PubMed ID: 35961859 [TBL] [Abstract][Full Text] [Related]
17. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Gunnarsson R; Mansouri L; Isaksson A; Göransson H; Cahill N; Jansson M; Rasmussen M; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Geisler C; Juliusson G; Rosenquist R Haematologica; 2011 Aug; 96(8):1161-9. PubMed ID: 21546498 [TBL] [Abstract][Full Text] [Related]
18. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation. Bracher S; Fuhrmann I; Jeromin S; Nadarajah N; Kern W; Haferlach T; Haferlach C; Stengel A Mol Biol Rep; 2022 Dec; 49(12):12247-12252. PubMed ID: 36169893 [TBL] [Abstract][Full Text] [Related]
19. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198 [TBL] [Abstract][Full Text] [Related]
20. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]